Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 10/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310251 | 1.00 | ADRB2 (0.42) | ADRB2ADRB1MRGPRX4 | |
| SCHEMBL1310611 | 0.94 | ADRB2 (0.39) | ADRB2ADRB1MRGPRX4 | |
| SCHEMBL1310613 | 0.94 | ADRB2 (0.39) | ADRB2ADRB1MRGPRX4 | |
| SCHEMBL6255658 | 0.91 | ADRB2 (0.40) | ADRB2ADRB1 | |
| SCHEMBL6255656 | 0.91 | ADRB2 (0.40) | ADRB2ADRB1 | |
| SCHEMBL2142394 | 0.91 | ADRB2 (0.42) | ADRB2ADRB1 | |
| SCHEMBL2142402 | 0.91 | ADRB2 (0.42) | ADRB2ADRB1 | |
| SCHEMBL28435966 | 0.83 | POLB (0.39) | ADRB2ADRB1 | |
| SCHEMBL17985832 | 0.83 | POLB (0.39) | ADRB2ADRB1 | |
| SCHEMBL2140532 | 0.82 | ADRB2 (0.41) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450490-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2569285-A1 | BIFUNCTIONAL QUINOLINE DERIVATIVES | Gilead Sciences, Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367829-B2 | Bi-functional pyrazolopyridine compounds | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20130018050-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018050-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2011143105-A1 | BIFUNCTIONAL QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143106-A1 | BI - FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, MRGPRX2 | ADRB2 16/4885ADRB1 15/4885MRGPRX4 11/4885 |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, HRH2 | ADRB2 13/4885ADRB1 12/4885MRGPRX4 15/4885 |
| US-20130018050-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | BDKRB2, BDKRB1, P2RX7 | ADRB2 40/4885ADRB1 44/4885MRGPRX4 17/4885 |
| US-20110275623-A1 | BI-FUNCTIONAL PYRAZOLOPYRIDINE COMPOUNDS | BDKRB2, BDKRB1, P2RX7 | ADRB2 40/4885ADRB1 44/4885MRGPRX4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.